Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic testing and analysis expert Illumina
So what: The third-quarter results posted this morning missed revised, lower earnings estimates by a penny but made up for it with a strong view of next-quarter sales. That said, management warned that revenues depend heavily on government sales, and you just never know what Uncle Sam's research budgets will look like next year.
Now what: Illumina's success did not inspire a rally among the company's chief rivals: Affymetrics
Interested in more info about Illumina? Click here to add it to My Watchlist.